Article

Topical treatment habits in psoriasis patients receiving adalimumab.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Dermatology (impact factor: 2.05). 03/2012; 224(3):228-30. DOI:10.1159/000336776 pp.228-30
Source: PubMed

ABSTRACT Biologics are used increasingly to treat moderate-to-severe psoriasis. Here the topical treatment habits (corticosteroids and vitamin D derivates) and moisturizer use of 97 Swiss patients (male 65, female 32) receiving adalimumab have been evaluated.
Using a short cross-sectional survey the pharmacist asked patients during telephone contact about their topical treatment habits and psoriasis activity.
47 patients with adalimumab monotherapy were still free of psoriatic lesions after a longer follow-up of 13 months of therapy; 8 of them still used topical treatment. In contrast, 38 of 50 patients with remaining lesions used topicals. More than 75% of patients indicated that the perceived efficacy of additional topical therapy was ≥5 on a visual analog scale (0-10). The use of moisturizers did not correlate with disease activity.
Topical treatment use by adalimumab patients is associated with remaining disease activity. 83% of patients without residual plaques (40% of all adalimumab patients) are able to stop topical treatment completely.

0 0
 · 
0 Bookmarks
 · 
34 Views

Keywords

13 months
 
47 patients
 
50 patients
 
97 Swiss patients
 
adalimumab monotherapy
 
adalimumab patients
 
additional topical therapy
 
corticosteroids
 
moderate-to-severe psoriasis
 
moisturizer use
 
perceived efficacy
 
psoriatic lesions
 
residual plaques
 
short cross-sectional survey
 
telephone contact
 
topical treatment
 
topical treatment habits
 
Topical treatment use
 
visual analog scale
 
vitamin D derivates